DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/djjtkr/alpha6_beta4) has announced the addition of the "Alpha6 Beta4 Integrin Signaling Pathway in Oncology Drug Pipeline Update 2015" report to their offering.
The Alpha6 Beta4 Integrin signaling pathway activates the PI 3-kinase/Akt, MAPK/NFkB and SMAD signaling modules.
There are today 267 companies plus partners developing 353 Alpha6Beta4 integrin pathway targeting drugs in 1386 developmental projects in cancer. In addition, there are 2 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 198 drugs.
Alpha6 Beta4 Integrin Signaling Pathway In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 168 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 165 out of the 166 studied drug targets so far have been recorded with somatic mutations.
The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 38 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.
Pipeline Breakdown According to Number of Drugs
- Marketed - 34
- Registered - 1
- Pre-registration - 3
- Phase III - 40
- Phase II - 129
- Phase I - 166
- Preclinical - 192
- No Data - 9
- Suspended - 2
- Ceased - 198
For more information visit http://www.researchandmarkets.com/research/djjtkr/alpha6_beta4